4.6 Review

Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk

期刊

FRONTIERS IN MEDICINE
卷 9, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2022.914016

关键词

sex and gender; lipoproteins; autoimmunity; atherosclerosis; SLE

资金

  1. Versus Arthritis Career Development Fellowship [22856]
  2. NIHR UCLH Biomedical Research Centre [BRC772/III/EJ/101350, BRC773/III/CC/101350]
  3. Lupus UK
  4. Rosetrees Trust [M409]
  5. Versus Arthritis [21593, 20164]
  6. NIHR-Biomedical Research Centre at GOSH
  7. GOSCC
  8. NIHR-Biomedical Research Centres at UCLH

向作者/读者索取更多资源

Healthy women during childbearing years have a lower risk of cardiovascular disease compared to men, possibly due to lower levels of atherogenic lipoproteins and higher levels of atheroprotective lipoproteins. However, women with systemic lupus erythematosus face increased cardiovascular disease risk, which may be related to dyslipidaemia.
It is known that healthy women during childbearing years have a lower risk of cardiovascular disease (CVD) and coronary heart disease compared to age matched men. Various traditional risk factors have been shown to confer differential CVD susceptibilities by sex. Atherosclerosis is a major cause of CVD and mortality and sex differences in CVD risk could be due to reduced atherogenic low and very low-density lipoproteins (LDL and VLDL) and increased atheroprotective high density lipoproteins (HDLs) in women. In contrast, patients with systemic lupus erythematosus (SLE), a chronic inflammatory disease that predominately affects women, have an increased atherosclerotic and CVD risk. This increased CVD risk is largely associated with dyslipidaemia, the imbalance of atherogenic and atheroprotective lipoproteins, a conventional CVD risk factor. In many women with SLE, dyslipidaemia is characterised by elevated LDL and reduced HDL, eradicating the sex-specific CVD protection observed in healthy women compared to men. This review will explore this paradox, reporting what is known regarding sex differences in lipid metabolism and CVD risk in the healthy population and transgender individuals undergoing cross-sex hormone therapy, and provide evidence for how these differences may be compromised in an autoimmune inflammatory disease setting. This could lead to better understanding of mechanistic changes in lipid metabolism driving the increased CVD risk by sex and in autoimmunity and highlight potential therapeutic targets to help reduce this risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据